Promising preclinical models for lung cancer research—lung cancer organoids: a narrative review

Xinru Chen,Li Ye,Hao Wang,Xinyue Liu,Lishu Zhao,Kandi Xu,Yujin Liu,Yayi He

DOI: https://doi.org/10.21037/tlcr-23-341

2024-03-29

Translational Lung Cancer Research

Abstract:Keywords: Lung cancer; organoids; culture medium; preclinical models

oncology,respiratory system

What problem does this paper attempt to address?

Lung cancer organoids, a promising model still with long way to go

Hao-Chuan Ma,Yan-Juan Zhu,Rui Zhou,Ya-Ya Yu,Zhen-Zhen Xiao,Hai-Bo Zhang,Hao-chuan Ma,Yan-juan Zhu,Ya-ya Yu,Zhen-zhen Xiao,Hai-bo Zhang

DOI: https://doi.org/10.1016/j.critrevonc.2022.103610

IF: 6.625

2022-03-01

Critical Reviews in Oncology/Hematology

Abstract:Lung cancer organoids (LCOs) have sprung up in more and more researching fields, because of their ability to recapitulate the three-dimensional structure and functions of the in vivo counterpart organs. However, the culture system for LCOs is still immature, resulting in limited success rate and low tumor purity when culturing LCOs. This is mainly due to the deficiency of an optimal formula of culture medium specially for LCOs. Various cytokines and small molecules have been added in the LCOs culturing system. Compound screening, considering both the mechanism of these molecules and the complexity of lung cancer types is warranted to optimize LCOs culture medium. As methods to culture LCOs increase in sophistication, this model will undoubtedly stand its ground in the coming years in every aspect of cancer researches, especially with major advantages in the field of personalized medicine and tumor microenvironment researches.

oncology,hematology
Recent advances in lung cancer organoid (tumoroid) research (Review)

Qiang Zhang,Mingyang Zhang

DOI: https://doi.org/10.3892/etm.2024.12672

2024-08-01

Abstract:Lung cancer is the most critical type of malignant tumor that threatens human health. Traditional preclinical models have certain defects; for example, they cannot accurately reflect the characteristics of lung cancer and their development is costly and time-consuming. Through self-organization, cancer stem cells (CSCs) generate cancer organoids that have a structure similar to that of lung cancer tissues, overcoming to some extent the aforementioned challenges, thus enabling them to have broader application prospects. Lung cancer organoid (LCO) development methods can be divided into three broad categories based on the source of cells, which include cell lines, patient-derived xenografts and patient tumor tissue/pleural effusion. There are 17 different methods that have been described for the development of LCOs. These methods can be further merged into six categories based on the source of cells, the pre-treatment method used, the composition of the medium and the culture scaffold. These categories are: i) CSCs induced by defined transcription factors; ii) suspension culture; iii) relative optimal culture medium; iv) suboptimal culture medium; v) mechanical digestion and suboptimal culture medium; and vi) hydrogel scaffold. In the current review, the advantages and disadvantages of each of the aforementioned methods are summarized, and references for supporting studies are cited.
Lung cancer organoids: models for preclinical research and precision medicine

Yajing Liu,Yanbing Zhou,Pu Chen

DOI: https://doi.org/10.3389/fonc.2023.1293441

IF: 4.7

2023-10-25

Frontiers in Oncology

Abstract:Lung cancer is a malignancy with high incidence and mortality rates globally, and it has a 5-year survival rate of only 10%–20%. The significant heterogeneity in clinical presentation, histological features, multi-omics findings, and drug sensitivity among different lung cancer patients necessitate the development of personalized treatment strategies. The current precision medicine for lung cancer, primarily based on pathological and genomic multi-omics testing, fails to meet the needs of patients with clinically refractory lung cancer. Lung cancer organoids (LCOs) are derived from tumor cells within tumor tissues and are generated through three-dimensional tissue culture, enabling them to faithfully recapitulate in vivo tumor characteristics and heterogeneity. The establishment of a series of LCOs biobanks offers promising platforms for efficient screening and identification of novel targets for anti-tumor drug discovery. Moreover, LCOs provide supplementary decision-making factors to enhance the current precision medicine for lung cancer, thereby addressing the limitations associated with pathology-guided approaches in managing refractory lung cancer. This article presents a comprehensive review on the construction methods and potential applications of LCOs in both preclinical and clinical research. It highlights the significance of LCOs in biomarker exploration, drug resistance investigation, target identification, clinical precision drug screening, as well as microfluidic technology-based high-throughput drug screening strategies. Additionally, it discusses the current limitations and future prospects of this field.

oncology
Organoids in lung cancer: A teenager with infinite growth potential

Yiming Xu,Wanghao Xin,Chao Yan,Yangfeng Shi,Yeping Li,Yanjie Hu,Kejing Ying

DOI: https://doi.org/10.1016/j.lungcan.2022.08.006

IF: 6.081

2022-10-01

Lung Cancer

Abstract:Despite the rapid advancement in lung cancer research, morbidity and mortality remain high in recent years. Therefore, deeper learning of the underlying molecular mechanisms of pathogenesis and discovery of novel effective therapeutic strategies of treatment in lung cancer research are around the corner. Among these, applying an efficient and reliable preclinical model would be a critical step that exists throughout the whole process. Traditional 2D models used in lung cancer research, including lung cancer cell lines and cell-derived xenograft models, cannot recapitulate the situations of patients due to the lack of a tumor microenvironment or tumor heterogeneity. Organoids, newly developed 3D in vitro structures, more comprehensively imitate the architecture, interaction and genetics of human organs. Cancer organoids, especially those derived from individual patients, can better resemble primary tumor tissues and thus have a greater potential for making breakthroughs in future cancer studies. Here, we mainly review recent advances in the methodologies and applications of lung cancer organoids, which are just developing but have huge potential.

oncology,respiratory system
Organoids in Lung Cancer Management

Yushi Li,Joyce W. Y. Chan,Rainbow W. H. Lau,Winnie W. Y. Cheung,Alissa Michelle Wong,Aikha M. Wong,Nathalie Wong,Calvin Sze Hang Ng

DOI: https://doi.org/10.3389/fsurg.2021.753801

IF: 1.8

2021-12-09

Frontiers in Surgery

Abstract:Lung cancer is a complex milieu of genomically altered cancer cells, a diverse collection of differentiated cells and nonneoplastic stroma. Lung cancer organoids is a three-dimensional structure grown from patient cancer tissue that could mimic in vivo complex behavior and cellular architecture of the cancer. Furthermore, the genomic alterations of the primary lung tumor is captured ex vivo . Lung cancer organoids have become an important preclinical model for oncology studies in recent years. It could be used to model the development of lung cancer, investigate the process of tumorigenesis, and also study the signaling pathways. The organoids could also be a platform to perform drug screening and biomarker validation of lung cancer, providing a promising prediction of patient-specific drug response. In this review, we described how lung cancer organoids have opened new avenues for translating basic cancer research into clinical therapy and discussed the latest and future developments in organoid technology, which could be further applied in lung cancer organoids research.

surgery
Patient-derived cell line, xenograft and organoid models in lung cancer therapy

Ku-Geng Huo,Elisa D’Arcangelo,Ming-Sound Tsao

DOI: https://doi.org/10.21037/tlcr-20-154

2020-10-01

Translational Lung Cancer Research

Abstract:Lung cancer accounts for most cancer-related deaths worldwide and has an overall 5-year survival rate of ~15%. Cell lines have played important roles in the study of cancer biology and potential therapeutic targets, as well as pre-clinical testing of novel drugs. However, most experimental therapies that have cleared preclinical testing using established cell lines have failed phase III clinical trials. This suggests that such models may not adequately recapitulate patient tumor biology and clinical outcome predictions. Here, we discuss and compare different pre-clinical lung cancer models, including established cell lines, patient-derived cell lines, xenografts and organoids, summarize the methodology for generating these models, and review their relative advantages and limitations in different oncologic research applications. We further discuss additional gaps in patient-derived pre-clinical models to better recapitulate tumor biology and improve their clinical predictive power.

oncology,respiratory system
Applications of lung cancer organoids in precision medicine: from bench to bedside

Huihui Li,Zexin Chen,Ning Chen,Yun Fan,Yaping Xu,Xiaoling Xu

DOI: https://doi.org/10.1186/s12964-023-01332-9

2023-12-06

Abstract:As the leading cause of cancer-related mortality, lung cancer continues to pose a menacing threat to human health worldwide. Lung cancer treatment options primarily rely on chemoradiotherapy, surgery, targeted therapy, or immunotherapy. Despite significant progress in research and treatment, the 5-year survival rate for lung cancer patients is only 10-20%. There is an urgent need to develop more reliable preclinical models and valid therapeutic approaches. Patient-derived organoids with highly reduced tumour heterogeneity have emerged as a promising model for high-throughput drug screening to guide treatment of lung cancer patients. Organoid technology offers a novel platform for disease modelling, biobanking and drug development. The expected benefit of organoids is for cancer patients as the subsequent precision medicine technology. Over the past few years, numerous basic and clinical studies have been conducted on lung cancer organoids, highlighting the significant contributions of this technique. This review comprehensively examines the current state-of-the-art technologies and applications relevant to the formation of lung cancer organoids, as well as the potential of organoids in precision medicine and drug testing. Video Abstract.
Cancer organoids: A platform in basic and translational research

Xin Ma,Qin Wang,Guozheng Li,Hui Li,Shouping Xu,Da Pang

DOI: https://doi.org/10.1016/j.gendis.2023.02.052

IF: 7.376

2023-04-01

Genes & Diseases

Abstract:An accumulation of previous work has established organoids as good preclinical models of human tumors, facilitating translation from basic research to clinical practice. They are changing the paradigm of preclinical cancer research because they can recapitulate the heterogeneity and pathophysiology of human cancers and more closely approximate the complex tissue environment and structure found in clinical tumors than in vitro cell lines and animal models. However, the potential applications of cancer organoids remain to be comprehensively summarized. In the review, we firstly describe what is currently known about cancer organoid culture and then discuss in depth the basic mechanisms, including tumorigenesis and tumor metastasis, and describe recent advances in patient-derived tumor organoids (PDOs) for drug screening and immunological studies. Finally, the present challenges faced by organoid technology in clinical practice and its prospects are discussed. This review highlights that organoids may offer a novel therapeutic strategy for cancer research.

genetics & heredity,biochemistry & molecular biology
Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review

Leqing Zhu,Jianhua Zhang,Quanwei Guo,Jun Kuang,Dongfang Li,Mengxi Wu,Yijun Mo,Tao Zhang,Xinghua Gao,Jianfeng Tan

DOI: https://doi.org/10.3389/fbioe.2023.1299033

IF: 5.7

2023-11-08

Frontiers in Bioengineering and Biotechnology

Abstract:Lung cancer has become the primary cause of cancer-related deaths because of its high recurrence rate, ability to metastasise easily, and propensity to develop drug resistance. The wide-ranging heterogeneity of lung cancer subtypes increases the complexity of developing effective therapeutic interventions. Therefore, personalised diagnostic and treatment strategies are required to guide clinical practice. The advent of innovative three-dimensional (3D) culture systems such as organoid and organ-on-a-chip models provides opportunities to address these challenges and revolutionise lung cancer research and drug evaluation. In this review, we introduce the advancements in lung-related 3D culture systems, with a particular focus on lung organoids and lung-on-a-chip, and their latest contributions to lung cancer research and drug evaluation. These developments include various aspects, from authentic simulations and mechanistic enquiries into lung cancer to assessing chemotherapeutic agents and targeted therapeutic interventions. The new 3D culture system can mimic the pathological and physiological microenvironment of the lung, enabling it to supplement or replace existing two-dimensional culture models and animal experimental models and realize the potential for personalised lung cancer treatment.

multidisciplinary sciences
Application of organoids in precision immunotherapy of lung cancer (Review)

Huichuan Tian,Jiajun Ren,Ruiyu Mou,Yingjie Jia

DOI: https://doi.org/10.3892/ol.2023.14071

2023-09-26

Abstract:In immunotherapy, the immune system is modulated in order to treat cancer. Traditional two dimensional in vitro models and in vivo animal models are insufficient to simulate the complex tumor microenvironment (TME) in the original tumor. As tumor immunotherapy involves the immune system, additional tumor mimic models, such as patient-derived organoids, are required for the evaluation of the efficacy of immunotherapy. Furthermore, non-tumor components and host tumor cells in the TME may interact to promote cancer incidence, progression, drug resistance and metastasis. It is possible to produce organoid models for lung cancer by retaining endogenous stromal components (e.g., multiple immune cell types), supplying cancer-associated fibroblasts and exogenous immune cells, constructing tumor vasculature and adding other biological or chemical components that emulate the TME. Therefore, the lung cancer organoid culture platform may facilitate preclinical testing of immunotherapy drugs for lung cancer by mimicking immunotherapy responses. The present review summarizes current lung cancer organoid culture methods for TME modeling and discusses the use of lung cancer-derived organoids for the detection of lung cancer immunotherapy and individualized cancer immunotherapy.
Scientific Validation and Clinical Application of Lung Cancer Organoids

Dahye Lee,Yoonjoo Kim,Chaeuk Chung

DOI: https://doi.org/10.3390/cells10113012

IF: 6

2021-11-04

Cells

Abstract:Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of normal cell organoids especially in LCOs from intrapulmonary lesions. Several modified media are specifically utilized for promoting the cancer cell’s growth. For culturing high-purity LCOs, cancer cells from metastatic lesions and malignant effusions are used. Recently, single-cell RNA sequencing has identified previously unknown cell populations in the lungs and lung cancer. This sequencing technology can be used to validate whether the LCO recapitulates the heterogeneity and functional hierarchy of the primary tumor. Several groups have attempted to culture LCOs with mesenchymal cells and immune cells to recapitulate the tumor microenvironment. Disease modeling using LCO provides novel insight into the pathophysiology of lung cancer and enables high-throughput screening for drug discovery and prognosis prediction. An LCO model would help to identify new concepts as a basis for lung cancer targeting by discovering innovative therapeutic targets.

cell biology
Organoids: Construction and Application in Gastric Cancer

Chengdong Huo,Xiaoxia Zhang,Yanmei Gu,Daijun Wang,Shining Zhang,Tao Liu,Yumin Li,Wenting He

DOI: https://doi.org/10.3390/biom13050875

IF: 6.064

2023-01-01

Biomolecules

Abstract:Gastric organoids are biological models constructed in vitro using stem cell culture and 3D cell culture techniques, which are the latest research hotspots. The proliferation of stem cells in vitro is the key to gastric organoid models, making the cell subsets within the models more similar to in vivo tissues. Meanwhile, the 3D culture technology also provides a more suitable microenvironment for the cells. Therefore, the gastric organoid models can largely restore the growth condition of cells in terms of morphology and function in vivo. As the most classic organoid models, patient-derived organoids use the patient’s own tissues for in vitro culture. This kind of model is responsive to the ‘disease information’ of a specific patient and has great effect on evaluating the strategies of individualized treatment. Herein, we review the current literature on the establishment of organoid cultures, and also explore organoid translational applications.
Organoids: approaches and utility in cancer research

Bingrui Zhou,Zhiwei Feng,Jun Xu,Jun Xie

DOI: https://doi.org/10.1097/cm9.0000000000002477

IF: 6.133

2023-06-27

Chinese Medical Journal

Abstract:ABSTRACT: Organoids are three-dimensional cellular structures with self-organizing and self-differentiation capacities. They faithfully recapitulate structures and functions of in vivo organs as represented by functionality and microstructural definitions. Heterogeneity in in vitro disease modeling is one of the main reasons for anti-cancer therapy failures. Establishing a powerful model to represent tumor heterogeneity is crucial for elucidating tumor biology and developing effective therapeutic strategies. Tumor organoids can retain the original tumor heterogeneity and are commonly used to mimic the cancer microenvironment when co-cultured with fibroblasts and immune cells; therefore, considerable effort has been made recently to promote the use of this new technology from basic research to clinical studies in tumors. In combination with gene editing technology and microfluidic chip systems, engineered tumor organoids show promising abilities to recapitulate tumorigenesis and metastasis. In many studies, the responses of tumor organoids to various drugs have shown a positive correlation with patient responses. Owing to these consistent responses and personalized characteristics with patient data, tumor organoids show excellent potential for preclinical research. Here, we summarize the properties of different tumor models and review their current state and progress in tumor organoids. We further discuss the substantial challenges and prospects in the rapidly developing tumor organoid field.

medicine, general & internal
Lung Cancer Organoids: The Rough Path to Personalized Medicine

Rachele Rossi,Maria Laura De Angelis,Eljona Xhelili,Giovanni Sette,Adriana Eramo,Ruggero De Maria,Ursula Cesta Incani,Federica Francescangeli,Ann Zeuner

DOI: https://doi.org/10.3390/cancers14153703

2022-07-30

Cancers

Abstract:Lung cancer is the leading cause of cancer death worldwide. Despite significant advances in research and therapy, a dismal 5-year survival rate of only 10–20% urges the development of reliable preclinical models and effective therapeutic tools. Lung cancer is characterized by a high degree of heterogeneity in its histology, a genomic landscape, and response to therapies that has been traditionally difficult to reproduce in preclinical models. However, the advent of three-dimensional culture technologies has opened new perspectives to recapitulate in vitro individualized tumor features and to anticipate treatment efficacy. The generation of lung cancer organoids (LCOs) has encountered greater challenges as compared to organoids derived from other tumors. In the last two years, many efforts have been dedicated to optimizing LCO-based platforms, resulting in improved rates of LCO production, purity, culture timing, and long-term expansion. However, due to the complexity of lung cancer, further advances are required in order to meet clinical needs. Here, we discuss the evolution of LCO technology and the use of LCOs in basic and translational lung cancer research. Although the field of LCOs is still in its infancy, its prospective development will likely lead to new strategies for drug testing and biomarker identification, thus allowing a more personalized therapeutic approach for lung cancer patients.

oncology
Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening

Zhichao Li,Youhui Qian,Wujiao Li,Lisa Liu,Lei Yu,Xia Liu,Guodong Wu,Youyu Wang,Weibin Luo,Fuyuan Fang,Yuchen Liu,Fei Song,Zhiming Cai,Wei Chen,Weiren Huang

DOI: https://doi.org/10.1016/j.isci.2020.101411

IF: 5.8

2020-01-01

iScience

Abstract:Lung cancer is an extremely heterogeneous disease, and its treatment remains one of the most challenging tasks in medicine. Few existing laboratory lung cancer models can faithfully recapitulate the diversity of the disease and predict therapy response. Here, we establish 12 patient-derived organoids from the most common lung cancer subtype, lung adenocarcinoma (LADC). Extensive gene and histopathology profiling show that the tumor organoids retain the histological architectures, genomic landscapes, and gene expression profiles of their parental tumors. Patient-derived lung cancer organoids are amenable for biomarker identification and high-throughput drug screening in vitro. This study should enable the generation of patient-derived lung cancer organoid lines, which can be used to further the understanding of lung cancer pathophysiology and to assess drug response in personalized medicine.
Cancer organoid co-culture model system: Novel approach to guide precision medicine

Jin Yuan,Xiaoyang Li,Shengji Yu

DOI: https://doi.org/10.3389/fimmu.2022.1061388

IF: 7.3

2023-01-13

Frontiers in Immunology

Abstract:Three-dimensional cancer organoids derived from self-organizing cancer stems are ex vivo miniatures of tumors that faithfully recapitulate their structure, distinctive cancer features, and genetic signatures. As novel tools, current cancer organoids have been well established and rapidly applied in drug testing, genome editing, and transplantation, with the ultimate aim of entering clinical practice for guiding personalized therapy. However, given that the lack of a tumor microenvironment, including immune cells and fibrous cells, is a major limitation of this emerging methodology, co-culture models inspire high hope for further application of this technology in cancer research. Co-culture of cancer organoids and immune cells or fibroblasts is available to investigate the tumor microenvironment, molecular interactions, and chimeric antigen receptor-engineered lymphocytes in cancer treatment. In light of the recent progress in cancer organoid co-culture models, it is only possible to recognize the advantages and drawbacks of this novel model to exploit its full potential. In this review, we summarize the recent advances in the application of cancer organoids and co-culture models and how they could be improved in the future to benefit cancer research, especially precision medicine.

immunology
Primary liver cancer organoids and their application to research and therapy

Xiaobin Zhu,Rajiv Trehan,Changqing Xie

DOI: https://doi.org/10.1016/j.jncc.2024.06.002

2024-06-17

Abstract:Primary liver cancer is a leading cause of death worldwide. To create advanced treatments for primary liver cancer, studies have utilized models such as 2D cell culture and in vivo animal models. Recent developments in cancer organoids have created the possibility for 3D in vitro cultures that recapitulates the cancer cell structure and operation as well as the tumor microenvironment (TME). However, before organoids can be directly translated to clinical use, tissue processing and culture medium must be standardized with unified protocols to decrease variability in results. Herein, we present the wide variety of published methodologies used to derive liver cancer organoids from patient tumor tissues. Additionally, we summarize validation methodologies for organoids in terms of marker expression levels with immunohistochemistry as well as the presence of mutations and variants through RNA-sequencing. Primary liver cancer organoids have exciting applications allowing for faster drug testing at a larger scale. Primary liver cancer organoids also assisit in uncovering new mechanisms. Through the coculture of different immune cells and cancer organoids, organoids are now better able to recapitulate the liver cancer TME. In addition, it further aids in the investigation of drug development and drug resistance. Lastly, we posit that the usage of liver cancer organoids in animal models provides researchers a methodology to overcome the current limitations of culture systems.
Tumor organoids: From inception to future in cancer research

Liang Yang,Shuo Yang,Xinyu Li,Bowen Li,Yan Li,Xiaodong Zhang,Yingbo Ma,Xueqiang Peng,Hongyuan Jin,Qing Fan,Shibo Wei,Jingang Liu,Hangyu Li

DOI: https://doi.org/10.1016/j.canlet.2019.04.005

2019-07-10

Abstract:Tumor models have created new avenues for personalized medicine and drug development. A new culture model derived from a three-dimensional system, the tumor organoid, is gradually being used in many fields. An organoid can simulate the physiological structure and function of tissue in situ and maintain the characteristics of tumor cells in vivo, overcoming the disadvantages of traditional experimental tumor models. Organoids can mimic pathological features of tumors and maintain genetic stability, making them suitable for both molecular mechanism studies and pharmacological experiments of clinical transformation. In addition, the application of tumor organoids combined with other technologies, such as liquid biopsy technology, microraft array (MRA), and high-content screening (HCS), for the development of personalized diagnosis and cancer treatment has a promising future. In this review, we introduce the evolution of organoids and discuss their specific application and advantages. We also summarize the characteristics of several tumor organoids culture systems.
Organoid As a Promising Tool for Primary Liver Cancer Research: a Comprehensive Review

Xuekai Hu,Jiayun Wei,Pinyan Liu,Qiuxia Zheng,Yue Zhang,Qichen Zhang,Jia Yao,Jingman Ni

DOI: https://doi.org/10.1186/s13578-024-01287-5

2024-01-01

Cell & Bioscience

Abstract:Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine.

Promising preclinical models for lung cancer research—lung cancer organoids: a narrative review

Lung cancer organoids, a promising model still with long way to go

Recent advances in lung cancer organoid (tumoroid) research (Review)

Lung cancer organoids: models for preclinical research and precision medicine

Organoids in lung cancer: A teenager with infinite growth potential

Organoids in Lung Cancer Management

Patient-derived cell line, xenograft and organoid models in lung cancer therapy

Applications of lung cancer organoids in precision medicine: from bench to bedside

Cancer organoids: A platform in basic and translational research

Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review

Application of organoids in precision immunotherapy of lung cancer (Review)

Scientific Validation and Clinical Application of Lung Cancer Organoids

Organoids: Construction and Application in Gastric Cancer

Organoids: approaches and utility in cancer research

Lung Cancer Organoids: The Rough Path to Personalized Medicine

Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening

Cancer organoid co-culture model system: Novel approach to guide precision medicine

Primary liver cancer organoids and their application to research and therapy

Tumor organoids: From inception to future in cancer research

Organoid As a Promising Tool for Primary Liver Cancer Research: a Comprehensive Review